StockGuru Leader Board: Pharmacyclics (NASDAQ: PCYC) Closed Up 17.34% on Friday

Pharmacyclics (NASDAQ: PCYC) is on The StockGuru Leader Board today.  The stock closed up 17.34% on Friday.

Volume was 3,936,511 shares traded.

About the Company:

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. Its products in clinical development includes PCI-32765, an orally active small molecule inhibitor of Bruton’s tyrosine kinase (Btk), which is in phase II studies for the treatment of patients with B-cell lymphoma or leukemia; PCI-27483, an inhibitor of Factor VIIa, which is in phase II clinical trial for the treatment of pancreatic cancer; PCI-24781, a histone deacetylase (HDAC) inhibitor in phase I and II clinical trials in solid tumors and hematological malignancies; HDAC8 Isoform-specific Inhibitor for T-cell leukemia and lymphoma, neuroblastoma, and autoimmune disease. The company’s pre-clinical programs include Btk inhibitor program for autoimmune disease; and HDAC8 inhibitor program for cancer. The company has a license agreement with the University of Texas to develop and commercialize porphyrins; expanded porphyrins, such as motexafin gadolinium; and other porphyrin-like substances. It also has a collaboration and license agreement with Servier. The company was founded in 1991 and is headquartered in Sunnyvale, California.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact:
IR Affiliates –
StoneBridge Web & SEO –

All content on is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070